Pimozide for schizophrenia or related psychoses. (Q33909324)

29 July 2017

1 reference

title

Pimozide for schizophrenia or related psychoses. (English)

1 reference

29 July 2017

Pimozide for schizophrenia or related psychoses (English)

0 references

1 reference

A Sultana

1

1 reference

29 July 2017

T McMonagle

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

2000

0 references

published in

1 reference

29 July 2017

CD001949

1 reference

29 July 2017

2

1 reference

Pimozide in the treatment of newly admitted schizophrenic patients

29 July 2017

3

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Medico-social evaluation of the long-term pharmacotherapy of schizophrenia. Comparative study of fluphenazine and pimozide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Token Economy, Pimozide and Chronic Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

An International Double‐Blind Clinical Evaluation of Pimozide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Pimozide in the maintenance treatment of apathetic and emotionally withdrawn schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Short-term outcome in trial entrants and trial eligible patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Pimozide in acute schizophrenia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

The Northwick Park "functional" psychosis study: diagnosis and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Psychopharmacology for dermatologic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Psychopharmacologic treatment of negative schizophrenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Lack of gender differences in neuroleptic response in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

A comparative double-blind trial of pimozide in stress-induced psychic and functional disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Development of a schizophrenia scale sensitive to change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Impact of substance abuse on the course and outcome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Delusional disorder (paranoia)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

A review of cognitive behavioral and pharmacological treatment of body dysmorphic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: Pimozide versus fluphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. The Scottish Schizophrenia Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

The Scottish First Episode Schizophrenia Study. III. Cognitive performance. The Scottish Schizophrenia Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

The Scottish First Episode Schizophrenia Study V. One-year follow-up. The Scottish Schizophrenia Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

A comparative double blind trial of pimozide and fluphenazine in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

A randomised controlled trial of prophylactic neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

A pilot study of pimozide in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

NATURE AND TREATMENT OF DELUSIONAL PARASITOSIS: A DIFFERENT EXPERIENCE IN INDIA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Therapeutic measures in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

Post-mortem antipsychotic drug concentrations and unexplained deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001949

10.1002/14651858.CD001949

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference